Clinical predictors of GH deficiency in surgically cured acromegalic patients

Cheol Ryong Ku, Jae Won Hong, Eui Hyun Kim, Sun Ho Kim, Eunjig Lee

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: Even in patients with cured acromegaly, GH deficiency (GHD) after transsphenoidal adenomectomy (TSA) adversely affects body composition and inflammatory biomarkers of cardiovascular risk. In this study, clinical parameters for predicting GHD after TSA in 123 cured acromegalic patients were investigated.

Design and methods: GH levels were measured at 6, 12, 18, 24, 48, and 72 h after TSA and serial insulin tolerance tests were conducted at 6 months, 2 years, and then every 2 years after TSA.

Results: GHD was found in 12 patients (9.8%) at 4.1 (range: 0.5-4.1) years after TSA. IGF1 levels were significantly lower at 6 months after TSA in GHD group than intact GH group (175.9 vs 316.8 μg/l, range: 32.0-425.0 and 96.9-547.3 respectively, P=0.008). Adenomas involving both sides of the pituitary gland were significantly more frequent in GHD patients (29.7 vs 83.3%; P=0.002). Furthermore, immediate postoperative 72-h GH levels after TSA were significantly lower (0.17 vs 0.45, range: 0.02-0.93 and 0.02-5.95 respectively, P=0.019) in GHD patients. In multiple logistic regression analysis, bilaterality of tumor involvement (odds ratio (OR) =10.678, P=0.003; 95% CI=2.248-50.728) and immediate postoperative 72-h GH level (OR=0.079, P=0.047; 95% CI=0.006-0.967) showed significant power for predicting GHD.

Conclusions: These data suggest that bilateral involvement of a pituitary adenoma and severely decreased immediate postoperative serum GH levels at 72 h after TSA may be independent risks factor for accelerated GHD in acromegalic patients.

Original languageEnglish
Pages (from-to)379-387
Number of pages9
JournalEuropean Journal of Endocrinology
Volume171
Issue number3
DOIs
Publication statusPublished - 2014 Sep 1

Fingerprint

Odds Ratio
Acromegaly
Pituitary Neoplasms
Pituitary Gland
Body Composition
Adenoma
Biomarkers
Logistic Models
Regression Analysis
Insulin
Serum
Neoplasms

All Science Journal Classification (ASJC) codes

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Ku, Cheol Ryong ; Hong, Jae Won ; Kim, Eui Hyun ; Kim, Sun Ho ; Lee, Eunjig. / Clinical predictors of GH deficiency in surgically cured acromegalic patients. In: European Journal of Endocrinology. 2014 ; Vol. 171, No. 3. pp. 379-387.
@article{ce914b4ac5e04125a459d0f78ef1b55a,
title = "Clinical predictors of GH deficiency in surgically cured acromegalic patients",
abstract = "Objective: Even in patients with cured acromegaly, GH deficiency (GHD) after transsphenoidal adenomectomy (TSA) adversely affects body composition and inflammatory biomarkers of cardiovascular risk. In this study, clinical parameters for predicting GHD after TSA in 123 cured acromegalic patients were investigated.Design and methods: GH levels were measured at 6, 12, 18, 24, 48, and 72 h after TSA and serial insulin tolerance tests were conducted at 6 months, 2 years, and then every 2 years after TSA.Results: GHD was found in 12 patients (9.8{\%}) at 4.1 (range: 0.5-4.1) years after TSA. IGF1 levels were significantly lower at 6 months after TSA in GHD group than intact GH group (175.9 vs 316.8 μg/l, range: 32.0-425.0 and 96.9-547.3 respectively, P=0.008). Adenomas involving both sides of the pituitary gland were significantly more frequent in GHD patients (29.7 vs 83.3{\%}; P=0.002). Furthermore, immediate postoperative 72-h GH levels after TSA were significantly lower (0.17 vs 0.45, range: 0.02-0.93 and 0.02-5.95 respectively, P=0.019) in GHD patients. In multiple logistic regression analysis, bilaterality of tumor involvement (odds ratio (OR) =10.678, P=0.003; 95{\%} CI=2.248-50.728) and immediate postoperative 72-h GH level (OR=0.079, P=0.047; 95{\%} CI=0.006-0.967) showed significant power for predicting GHD.Conclusions: These data suggest that bilateral involvement of a pituitary adenoma and severely decreased immediate postoperative serum GH levels at 72 h after TSA may be independent risks factor for accelerated GHD in acromegalic patients.",
author = "Ku, {Cheol Ryong} and Hong, {Jae Won} and Kim, {Eui Hyun} and Kim, {Sun Ho} and Eunjig Lee",
year = "2014",
month = "9",
day = "1",
doi = "10.1530/EJE-14-0304",
language = "English",
volume = "171",
pages = "379--387",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "3",

}

Clinical predictors of GH deficiency in surgically cured acromegalic patients. / Ku, Cheol Ryong; Hong, Jae Won; Kim, Eui Hyun; Kim, Sun Ho; Lee, Eunjig.

In: European Journal of Endocrinology, Vol. 171, No. 3, 01.09.2014, p. 379-387.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical predictors of GH deficiency in surgically cured acromegalic patients

AU - Ku, Cheol Ryong

AU - Hong, Jae Won

AU - Kim, Eui Hyun

AU - Kim, Sun Ho

AU - Lee, Eunjig

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Objective: Even in patients with cured acromegaly, GH deficiency (GHD) after transsphenoidal adenomectomy (TSA) adversely affects body composition and inflammatory biomarkers of cardiovascular risk. In this study, clinical parameters for predicting GHD after TSA in 123 cured acromegalic patients were investigated.Design and methods: GH levels were measured at 6, 12, 18, 24, 48, and 72 h after TSA and serial insulin tolerance tests were conducted at 6 months, 2 years, and then every 2 years after TSA.Results: GHD was found in 12 patients (9.8%) at 4.1 (range: 0.5-4.1) years after TSA. IGF1 levels were significantly lower at 6 months after TSA in GHD group than intact GH group (175.9 vs 316.8 μg/l, range: 32.0-425.0 and 96.9-547.3 respectively, P=0.008). Adenomas involving both sides of the pituitary gland were significantly more frequent in GHD patients (29.7 vs 83.3%; P=0.002). Furthermore, immediate postoperative 72-h GH levels after TSA were significantly lower (0.17 vs 0.45, range: 0.02-0.93 and 0.02-5.95 respectively, P=0.019) in GHD patients. In multiple logistic regression analysis, bilaterality of tumor involvement (odds ratio (OR) =10.678, P=0.003; 95% CI=2.248-50.728) and immediate postoperative 72-h GH level (OR=0.079, P=0.047; 95% CI=0.006-0.967) showed significant power for predicting GHD.Conclusions: These data suggest that bilateral involvement of a pituitary adenoma and severely decreased immediate postoperative serum GH levels at 72 h after TSA may be independent risks factor for accelerated GHD in acromegalic patients.

AB - Objective: Even in patients with cured acromegaly, GH deficiency (GHD) after transsphenoidal adenomectomy (TSA) adversely affects body composition and inflammatory biomarkers of cardiovascular risk. In this study, clinical parameters for predicting GHD after TSA in 123 cured acromegalic patients were investigated.Design and methods: GH levels were measured at 6, 12, 18, 24, 48, and 72 h after TSA and serial insulin tolerance tests were conducted at 6 months, 2 years, and then every 2 years after TSA.Results: GHD was found in 12 patients (9.8%) at 4.1 (range: 0.5-4.1) years after TSA. IGF1 levels were significantly lower at 6 months after TSA in GHD group than intact GH group (175.9 vs 316.8 μg/l, range: 32.0-425.0 and 96.9-547.3 respectively, P=0.008). Adenomas involving both sides of the pituitary gland were significantly more frequent in GHD patients (29.7 vs 83.3%; P=0.002). Furthermore, immediate postoperative 72-h GH levels after TSA were significantly lower (0.17 vs 0.45, range: 0.02-0.93 and 0.02-5.95 respectively, P=0.019) in GHD patients. In multiple logistic regression analysis, bilaterality of tumor involvement (odds ratio (OR) =10.678, P=0.003; 95% CI=2.248-50.728) and immediate postoperative 72-h GH level (OR=0.079, P=0.047; 95% CI=0.006-0.967) showed significant power for predicting GHD.Conclusions: These data suggest that bilateral involvement of a pituitary adenoma and severely decreased immediate postoperative serum GH levels at 72 h after TSA may be independent risks factor for accelerated GHD in acromegalic patients.

UR - http://www.scopus.com/inward/record.url?scp=84907197812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907197812&partnerID=8YFLogxK

U2 - 10.1530/EJE-14-0304

DO - 10.1530/EJE-14-0304

M3 - Article

VL - 171

SP - 379

EP - 387

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 3

ER -